temelimab: Clinical Trials

7 trials of temelimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 terminated. 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 27Completed 5, Terminated 2

Follow temelimab: new trials by email Literature Review of temelimab trials Research Report on temelimab

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome
Temelimab 54mg/kg, Placebo - Post-COVID-19 Syndrome
Phase 2CompletedGeNeuro SA2032022-08-292024-05-17
A Long-term Extension of Study GNC-401
Temelimab 18 mg/kg, Temelimab 36mg/kg, Temelimab 54 mg/kg - Multiple Sclerosis
Phase 2TerminatedGeNeuro Innovation SAS332021-08-272022-07-07
Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis
temelimab 18 mg/kg, temelimab 36 mg/kg, temelimab 54 mg/kg - Multiple Sclerosis
Phase 2CompletedGeNeuro Innovation SAS412020-06-172024-11-07
Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years
GNbAC1, Placebo - Diabetes Mellitus Type 1
Phase 2CompletedGeNeuro Australia PTY Ltd642017-06-142020-10-20
Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis
GNbAC1 Monoclonal Antibody - Multiple Sclerosis, Relapsing-Remitting
Phase 2TerminatedGeNeuro SA2202017-06-062020-10-20
Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS
GNbAC1, Placebo - Multiple Sclerosis, Relapsing-Remitting
Phase 2CompletedGeNeuro SA2702016-04-012020-10-20
Safety Study of GNbAC1 in Multiple Sclerosis Patients
GNbAC1, GNbAC1 placebo - Multiple Sclerosis
Phase 2CompletedGeNeuro Innovation SAS102012-07-012021-02-08

Conditions studied

Multiple Sclerosis (5)  ·  Multiple Sclerosis, Relapsing-Remitting (2)  ·  Diabetes Mellitus, Type 1 (1)  ·  Post-Acute COVID-19 Syndrome (1)

Sponsors

GeNeuro Innovation SAS (3)  ·  GeNeuro SA (3)  ·  GeNeuro Australia PTY Ltd (1)

Countries

Italy (3)  ·  Spain (3)  ·  Bulgaria (2)  ·  Croatia (2)  ·  Czechia (2)  ·  Estonia (2)  ·  Germany (2)  ·  Hungary (2)  ·  Poland (2)  ·  Russia (2)  ·  Serbia (2)  ·  Sweden (2)  ·  Switzerland (2)  ·  Ukraine (2)  ·  Australia (1)

Top investigators

David Leppert, MD (2)  ·  Patrice Lalive, MD (1)  ·  Tobias Derfuss, MD (1)

Results publications

PMID 34240656, PMID 25392325, PMID 42409185

NIH funding

2015 (1), 2019 (1)